Among the 82.1% of BRCA1/2 carriers who did not have prior clinical BRCA1/2 testing, the return of genomic result was the start of a diagnostic process aimed at deciding if the risk variants were associated with current or past disease.20 For those with a personal history of BRCA1/2-associated cancer, a diagnosis of HBOC syndrome was now clear and the recommended management was changed to align with NCCN guidelines and to offer cascade testing for at-risk family members. This evidence concerns the gene BRCA1 and cancer.